Complex carbohydrates in the prevention of nocturnal hypoglycaemia in diabetic children

M T Ververs1, C Rouwé, G P Smit

  • 1Department of Pediatrics, University Hospital, Groningen, The Netherlands.

Insights

Uncooked cornstarch, a complex carbohydrate, did not fully prevent nocturnal hypoglycemia in children with insulin-dependent diabetes mellitus. However, it did slow the drop in blood glucose levels compared to standard snacks.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Nutritional Science

Background:

  • Nocturnal hypoglycemia is a significant concern for children with insulin-dependent diabetes mellitus.
  • Complex carbohydrates are explored as a potential strategy to mitigate overnight blood glucose drops.

Purpose of the Study:

  • To evaluate the efficacy of uncooked cornstarch as a complex carbohydrate source in preventing nocturnal hypoglycemia in pediatric patients.
  • To compare the impact of a cornstarch-based snack versus a standard snack on overnight blood glucose control.

Main Methods:

  • A pilot study involving nine children (ages 9-18) with insulin-dependent diabetes mellitus.
  • Children underwent two overnight hospital admissions: one with a standard snack and one with a test snack (uncooked cornstarch).
  • Blood glucose monitoring and intervention for hypoglycemia (< or = 3.0 mmol/l or symptoms) were conducted.

Main Results:

  • Four out of nine children required intervention after the cornstarch snack, compared to six out of nine after the standard snack.
  • The cornstarch snack resulted in slower blood glucose decline overnight.
  • Fewer interventions were needed after the test snack (four) compared to the standard snack (six).

Conclusions:

  • While uncooked cornstarch did not entirely prevent nocturnal hypoglycemia in the studied dose, it demonstrated a trend towards improved overnight glucose stability.
  • Further research with adjusted dosages or formulations may be warranted to optimize the use of complex carbohydrates for nocturnal hypoglycemia prevention.

Related Concept Videos

Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: &#945;-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...